All News

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons on best practices for approaching complex care.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted therapy.

Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in overall hospital ratings, willingness to recommend, and staff responsiveness.

Patients living with HIV who were frail or prefrail had significantly poorer oral health-related quality of life compared with patients with HIV who were robust.

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or explanation.

This week, Robert F. Kennedy Jr sat before the Senate for 2 separate hearings, to decide the fate of his confirmation as secretary of HHS.

A looming Supreme Court ruling will answer questions about the legality of the Affordable Care Act mandate for providing some preventive care services at no cost.

Adam Colborn, JD, of AMCP, discusses the complexities of drug pricing and what policymakers must consider in efforts to reduce prices and increase access.

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while obinutuzumab/venetoclax does not significantly alter blood viscosity.

Older adults had a higher risk of dementia if they had varied levels of lipoprotein cholesterol.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Test your knowledge of the first issue of AJMC's anniversary year!

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune response, and tumor progression, though more research is needed.

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective NaV1.8 pain signal inhibitor, an alternative to opiates.

Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.

The asymptomatic nature of glaucoma makes it imperative to get consistent screening to catch the condition early.

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

A rapid correction of hyperglycemia could be associated with ophthalmic complications based on several cases.

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures underscores the need for targeted prevention strategies.

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the resveratrol oral supplement.

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).